Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion
Eli Lilly (LLY) announced an agreement to acquire Ajax Therapeutics for up to $2.3 billion, including upfront and milestone payments. The deal adds an experimental myelofibrosis drug to Lilly's oncology portfolio.
Key Numbers
Eli Lilly (NYSE: LLY) has agreed to acquire Ajax Therapeutics, a private biotech company focused on cancer therapies, in a deal valued at up to $2.3 billion. The consideration includes upfront payments and future milestone payments tied to development and regulatory achievements.
Deal Details
| Item | Detail |
|---|---|
| Total Value | Up to $2.3 billion |
| Upfront Payment | Not disclosed |
| Milestone Payments | Tied to achieving milestones |
| Payment Method | Cash |
| Expected Close | Q2 2026 |
Rationale for the Deal
The acquisition aligns with Lilly's strategy to expand its oncology pipeline, particularly in rare blood cancers. Ajax's lead candidate, AJ1-10595, is a first-in-class selective JAK2 inhibitor targeting bone marrow cancer cells, showing promising early clinical results for myelofibrosis.
Regulatory Hurdles
The deal will likely be reviewed by the U.S. Federal Trade Commission (FTC) and foreign investment laws. Given Ajax's small size, significant regulatory pushback is not expected, though any delay could impact the closing timeline.
Impact on Stocks
Eli Lilly's stock (LLY) showed little movement following the announcement, as the deal's value is relatively small compared to Lilly's market cap (over $800 billion). However, future success of the drug could support long-term revenue growth in the oncology segment.
Frequently Asked Questions
Found this useful? Share it